trending Market Intelligence /marketintelligence/en/news-insights/trending/rdngb0bonmu6ospk-dvnqw2 content esgSubNav
In This List

Fibrocell Science regains Nasdaq compliance

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Fibrocell Science regains Nasdaq compliance

Fibrocell Science Inc. regained compliance with Nasdaq's $1 minimum bid price listing requirement.

The Exton, Pa.-based cell and gene therapy company fell out of compliance with the listing rule in January.